Anti-VEGFs efficacious treatment for myopic choroidal neovascularization

Anti-VEGF injections for myopic choroidal neovascularization, administered at a much lower frequency than is required for typical age-related macular degeneration, are an effective treatment, according to results of major randomized clinical trials and a comprehensive review of the literature by a panel of experts, published in a new consensus statement on management.With myopia on the rise among young generations, the prevalence of pathologic myopia and myopic CNV is also expected to increase. The prevalence or myopia is 40% in East Asian countries, but in the U.S. it has reached 24%, and Europe has similar figures, as shown by the Rotterdam Study, Tien Yin Wong, MD, PhD, said.